Menu
We’re back at World Clinical Biomarkers & CDx Boston!
Join us to explore how you can harness the power of decentralization to drive global health equity.
With our universal, scalable and technology-agnostic platform now serving 750 customers across 72 countries, coupled with our expertise in developing and deploying decentralized genomic applications, we help you enhance patient and market access to relevant genomic information, and match patients to the right trials and treatments.
Development of an NGS-based ecDNA detection solution into a clinical trial device targeting oncogene amplification
September 5, 2024 | 03:10 to 03:40 PM | Track A
SPEAKERS
Julien Pontis, PhD
Technical Product Manager and Lead Scientist, SOPHiA GENETICS
Peter Krein, PhD
Vice President of Precision Medicine, Boundless Bio
David Lu, PhD
Director of Precision Medicine, Boundless Bio
It’s well established that patients with oncogene amplification generally do not benefit from standard-of-care cancer treatments and extrachromosomal DNA (ecDNA) has emerged as a unique biology of cancerous tumors.
Join us in this talk to hear about the Boundless Bio and SOPHiA GENETICS’s partnership on the development and validation of a prototype device for use in ecDNA-directed therapies.
Hear how the integration of ecDNA technology will impact the journey of patients with oncogene-amplified cancers.
Delve into the development and validation path to transform access to innovative precision therapies.
Learn about SOPHiA GENETICS’ unique ability to harmonize data derived from diverse genomic instruments and deploy as a robust, standardized solution enabling a decentralized model for clinical trial testing.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at [email protected] to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.
